bioRxivBioengineering
Improved humoral immunity and protection against influenza virus infection with a 3D porous biomaterial vaccine
H. Miwa, O. Q. Antao, K. M. Kelly-Scumpia, S. Baghdasarian, D. P. Mayer, L. Shang, G. M. Sanchez, M. M. Archang, P. O. Scumpia, J. S. Weinstein, D. Di Carlo
Abstract
New vaccine platforms that properly activate humoral immunity and generate neutralizing antibodies are required to combat emerging and re-emerging pathogens, including influenza virus. Biomaterial scaffolds with macroscale porosity have demonstrated tremendous promise in regenerative medicine where they have been shown to allow immune cell infiltration and subsequent activation, but whether these types of materials can serve as an immunization platform is unknown. We developed an injectable immunization platform that uses a slurry of antigen-loaded hydrogel microparticles that anneal to form a porous scaffold with high surface area for antigen uptake by infiltrating immune cells as the biomaterial degrades to maximize humoral immunity. Antigen-loaded-microgels elicited a robust cellular humoral immune response, with increased CD4+ T follicular helper (Tfh) cells and prolonged germinal center (GC) B cells comparable to the commonly used adjuvant, aluminum hydroxide (Alum). By simply increasing the weight fraction of polymer material, we enhanced material stiffness and further increased antigen-specific antibody titers superior to Alum. Vaccinating mice with inactivated influenza virus loaded into this more highly crosslinked formulation elicited a strong antibody response and provided better protection against a high dose viral challenge than Alum. Thus, we demonstrate that by tuning physical and chemical properties alone, we can enhance adjuvanticity and promote humoral immunity and protection against a pathogen, leveraging two different types of antigenic material: individual protein antigen and inactivated virus. The flexibility of the platform may enable design of new vaccines to enhance innate and adaptive immune cell programming to generate and tune high affinity antibodies, a promising approach to generate long-lasting immunity against specific pathogens.
- organism: mouse
- assay: protein sequence
- research focus: drug response / drug discovery
- research focus: cell type annotation
- research focus: cell signaling & trafficking
- research focus: development & morphogenesis
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection.
D. P. Mayer, M. Nelson, … J. S. Weinstein·bioRxiv·Jan 30, 2024
- Broad heterologous protection against Influenza A viruses by an adjuvant-free modular mucosal T-cell vaccine platform.
Rajesh Thangavel Yadav, Mansi Sharma, … S.K. Tripathi·bioRxiv·Jun 5, 2026
- Intranasal administration of split-inactivated influenza virus vaccine mixed with a novel adjuvant elicits protective antibodies against seasonal influenza viruses.
Michael A. Carlock, Katherine Lynn Cupo, Ted M. Ross·bioRxiv·Oct 23, 2025
- Sustained vaccine exposure elicits more rapid, consistent, and broad humoral immune responses to multivalent influenza vaccines
Olivia M. Saouaf, Ben S. Ou, … Eric Andrew Appel·Advanced SciencePeer-reviewed·Mar 17, 2025
- Accelerated vaccine induction of IgM neutralising antibody enables same day vaccine protection against a lethal influenza virus challenge
Y. Honda-Okubo, L. Li, … N. Petrovsky·bioRxiv·Feb 17, 2021
- A chimeric Ad5-Envp-VLP vaccine platform confers broad-spectrum immunity against emerging and re-emerging pathogens
Yuan Zhang, Caiqian Wang, … Ling Zhao·bioRxiv·Jul 3, 2025